Methods of treating cancer with an mTOR inhibitor
The present disclosure relates to methods for the treatment of diseases or disorders (e.g., cancer) with mTOR inhibitors. Specifically, the disclosure relates to methods of treating a subject having a cancer by administering a particular dosage of an mTOR inhibitor. In some embodiments this disclosure includes methods for delaying, preventing, or treating acquired resistance to RAS inhibitors using a dosage of an mTOR inhibitor. In some embodiments, this disclosure relates to methods of treating or preventing adverse events associated with administration of an mTOR inhibitor using tacrolimus.
1. A method of treating a subject having a cancer, the method comprising administering a dosage of about 6 mg/week to about 25 mg/week of a compound to the subject:
wherein the compound is
or a stereoisomer, tautomer, or oxepane isomer thereof, or pharmaceutically acceptable salt of any of the foregoing
wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, endometrial cancer, head and neck cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, renal cancer, thyroid cancer, vulvar cancer, and prostate cancer.
2. The method of claim 1 , wherein the dosage is about 6 mg/week to about 14 mg/week.
3. The method of claim 1 , wherein the dosage is administered via IV infusion.
4. The method of claim 3 , wherein the dosage is administered over about 0.5 hour to about 2 hours.
5. The method of claim 3 , wherein the dosage is administered over about 1 hour.
6. The method of claim 1 , wherein the subject is human.
7. The method of claim 1 , wherein the method further comprises administering a tacrolimus solution to the subject.
8. The method of claim 7 , wherein the tacrolimus solution comprises about 0.1 mg/mL to about 1 mg/mL tacrolimus.
9. The method of claim 7 , wherein the tacrolimus solution is administered 1, 2, 3, or 4 times daily.
10. The method of claim 7 , wherein the tacrolimus solution is administered on the day of administering the dosage or just prior to administering the dosage.
11. The method of claim 1 , wherein the liver cancer is hepatocellular carcinoma or cholangiocarcinoma, and rhabdomyosarcoma.
12. The method of claim 1 , wherein the cancer is a solid tumor.
13. The method of claim 1 , wherein the cancer is head and neck cancer.
14. The method of claim 1 , wherein the cancer is colorectal cancer and comprises a mutation of PIK3CA, an amplification of MYC, or a mutation of PIK3CA and an amplification of MYC.
15. The method of claim 1 , wherein the cancer is head and neck cancer and comprises a mutation of PIK3CA, a mutation of PTEN, or a mutation of PIK3CA and a mutation of PTEN.
16. The method of claim 11 , wherein the hepatocellular carcinoma comprises a mutation of NFE2L2.
17. The method of claim 1 , wherein the cancer is ovarian cancer and comprises a mutation of TSC2.
18. The method of claim 1 , wherein the cancer is pancreatic cancer and comprises a mutation of STK11, a KRAS G12C mutation, or a mutation of STK11 and a KRAS G12C mutation.
19. The method of claim 7 , wherein the tacrolimus solution treats or prevents mucositis in the subject that has been, is being, or will be treated with the compound inhibitor.
20. The method of claim 19 , wherein the mucositis is stomatitis.
21. A method of treating a subject having a cancer, the method comprising administering a dosage of about 6 mg/week to about 25 mg/week of a compound to the subject:
wherein the compound is
or a stereoisomer, tautomer, or oxepane isomer thereof, or pharmaceutically acceptable salt of any of the foregoing
wherein the cancer comprises a PIK3CA mutation, a PTEN mutation, a TSC1 mutation, a TSC2 mutation, or a combination thereof.
22. The method of claim 21 , wherein the cancer comprises a PTEN mutation.
23. The method of claim 22 , wherein the PTEN mutation is a dominant negative mutation.
24. The method of claim 21 , wherein the cancer comprises greater than about 95% clonality of pathogenic variants in one or more of PIK3CA, PTEN, TSC1, and TSC2, wherein the PTEN mutation is a dominant negative mutation.